Literature DB >> 25131084

Improved coating of pancreatic islets with regulatory T cells to create local immunosuppression by using the biotin-polyethylene glycol-succinimidyl valeric acid ester molecule.

K Gołąb1, S Kizilel2, T Bal2, M Hara3, M Zielinski3, R Grose1, O Savari1, X-J Wang1, L-J Wang1, M Tibudan1, A Krzystyniak4, N Marek-Trzonkowska4, J M Millis1, P Trzonkowski4, P Witkowski5.   

Abstract

BACKGROUND: We showed that T regulatory (Treg) cells can be attached to the surface of pancreatic islets providing local immunoprotection. Further optimization of the method can improve coating efficiency, which may prolong graft survival. In this study, we compared the effectiveness of two different molecules used for binding of the Tregs to the surface of pancreatic islets. Our aim was to increase the number of Treg cells attached to islets without compromising islets viability and function.
METHODS: The cell surface of human Treg cells and pancreatic islets was modified using biotin-polyethylene glycol-N-hydroxylsuccinimide (biotin-PEG-NHS) or biotin-PEG-succinimidyl valeric acid ester (biotin-PEG-SVA). Then, islets were incubated with streptavidin as islet/Treg cells binding molecule. Treg cells were stained with CellTracker CM-DiL dye and visualized using a Laser Scanning Confocal Microscope. The number of Treg cells attached per islets surface area was analyzed by Imaris software. The effect of coating on islet functionality was determined using the glucose-stimulated insulin response (GSIR) assay.
RESULTS: The coating procedure with biotin-PEG-SVA allowed for attaching 40% more Treg cells per 1 μm(2) of islet surface. Although viability was comparable, function of the islets after coating using the biotin-PEG-SVA molecule was better preserved than with NHS molecule. GSIR was 62% higher for islets coated with biotin-PEG-SVA compared to biotin-PEG-NHS.
CONCLUSION: Coating of islets with Treg cells using biotin-PEG-SVA improves effectiveness with better preservation of the islet function. Improvement of the method of coating pancreatic islets with Treg cells could further facilitate the effectiveness of this novel immunoprotective approach and translation into clinical settings.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25131084      PMCID: PMC4435942          DOI: 10.1016/j.transproceed.2014.05.075

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  10 in total

1.  Adoptive transfer of CD4+CD25+ regulatory cells combined with low-dose sirolimus and anti-thymocyte globulin delays acute rejection of renal allografts in Cynomolgus monkeys.

Authors:  Anlun Ma; Shijie Qi; Lijun Song; Yanxin Hu; Hao Dun; Eric Massicotte; Martine Dupuis; Pierre Daloze; Huifang Chen
Journal:  Int Immunopharmacol       Date:  2010-11-20       Impact factor: 4.932

2.  Beta-cell death and mass in syngeneically transplanted islets exposed to short- and long-term hyperglycemia.

Authors:  Montserrat Biarnés; Marta Montolio; Victor Nacher; Mercè Raurell; Joan Soler; Eduard Montanya
Journal:  Diabetes       Date:  2002-01       Impact factor: 9.461

3.  Coating human pancreatic islets with CD4(+)CD25(high)CD127(-) regulatory T cells as a novel approach for the local immunoprotection.

Authors:  Natalia Marek; Adam Krzystyniak; Ipek Ergenc; Olivia Cochet; Ryosuke Misawa; Ling-Jia Wang; Karolina Gołąb; Xiaojun Wang; German Kilimnik; Manami Hara; Seda Kizilel; Piotr Trzonkowski; J Michael Millis; Piotr Witkowski
Journal:  Ann Surg       Date:  2011-09       Impact factor: 12.969

4.  2008 Update from the Collaborative Islet Transplant Registry.

Authors:  Rodolfo Alejandro; Franca B Barton; Bernhard J Hering; Steve Wease
Journal:  Transplantation       Date:  2008-12-27       Impact factor: 4.939

5.  Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis.

Authors:  Adam P Kohm; Pamela A Carpentier; Holly A Anger; Stephen D Miller
Journal:  J Immunol       Date:  2002-11-01       Impact factor: 5.422

Review 6.  Regulatory T-cell therapy for transplantation: how many cells do we need?

Authors:  Qizhi Tang; Karim Lee
Journal:  Curr Opin Organ Transplant       Date:  2012-08       Impact factor: 2.640

7.  Administration of CD4+CD25highCD127- regulatory T cells preserves β-cell function in type 1 diabetes in children.

Authors:  Natalia Marek-Trzonkowska; Malgorzata Mysliwiec; Anita Dobyszuk; Marcelina Grabowska; Ilona Techmanska; Jolanta Juscinska; Magdalena A Wujtewicz; Piotr Witkowski; Wojciech Mlynarski; Anna Balcerska; Jolanta Mysliwska; Piotr Trzonkowski
Journal:  Diabetes Care       Date:  2012-06-20       Impact factor: 19.112

8.  Improvement in outcomes of clinical islet transplantation: 1999-2010.

Authors:  Franca B Barton; Michael R Rickels; Rodolfo Alejandro; Bernhard J Hering; Stephen Wease; Bashoo Naziruddin; Jose Oberholzer; Jon S Odorico; Marc R Garfinkel; Marlon Levy; Francois Pattou; Thierry Berney; Antonio Secchi; Shari Messinger; Peter A Senior; Paola Maffi; Andrew Posselt; Peter G Stock; Dixon B Kaufman; Xunrong Luo; Fouad Kandeel; Enrico Cagliero; Nicole A Turgeon; Piotr Witkowski; Ali Naji; Philip J O'Connell; Carla Greenbaum; Yogish C Kudva; Kenneth L Brayman; Meredith J Aull; Christian Larsen; Tom W H Kay; Luis A Fernandez; Marie-Christine Vantyghem; Melena Bellin; A M James Shapiro
Journal:  Diabetes Care       Date:  2012-07       Impact factor: 19.112

9.  In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes.

Authors:  Qizhi Tang; Kammi J Henriksen; Mingying Bi; Erik B Finger; Greg Szot; Jianqin Ye; Emma L Masteller; Hugh McDevitt; Mark Bonyhadi; Jeffrey A Bluestone
Journal:  J Exp Med       Date:  2004-06-07       Impact factor: 14.307

10.  Ex vivo expanded human regulatory T cells can prolong survival of a human islet allograft in a humanized mouse model.

Authors:  Douglas C Wu; Joanna Hester; Satish N Nadig; Wei Zhang; Piotr Trzonkowski; Derek Gray; Stephen Hughes; Paul Johnson; Kathryn J Wood
Journal:  Transplantation       Date:  2013-10-27       Impact factor: 4.939

  10 in total
  9 in total

Review 1.  Encapsulated Islet Transplantation: Where Do We Stand?

Authors:  Vijayaganapathy Vaithilingam; Sumeet Bal; Bernard E Tuch
Journal:  Rev Diabet Stud       Date:  2017-06-12

Review 2.  Nanotechnology in cell replacement therapies for type 1 diabetes.

Authors:  Alexander U Ernst; Daniel T Bowers; Long-Hai Wang; Kaavian Shariati; Mitchell D Plesser; Natalie K Brown; Tigran Mehrabyan; Minglin Ma
Journal:  Adv Drug Deliv Rev       Date:  2019-02-02       Impact factor: 15.470

Review 3.  Polymeric Scaffolds for Pancreatic Tissue Engineering: A Review.

Authors:  Nupur Kumar; Heer Joisher; Anasuya Ganguly
Journal:  Rev Diabet Stud       Date:  2018-03-10

Review 4.  Novel technologies to engineer graft for tolerance induction.

Authors:  Kyle B Woodward; Feng Wang; Hong Zhao; Esma S Yolcu; Haval Shirwan
Journal:  Curr Opin Organ Transplant       Date:  2016-02       Impact factor: 2.640

Review 5.  Nanotechnology Approaches to Modulate Immune Responses to Cell-based Therapies for Type 1 Diabetes.

Authors:  Sydney C Wiggins; Nicholas J Abuid; Kerim M Gattás-Asfura; Saumadritaa Kar; Cherie L Stabler
Journal:  J Diabetes Sci Technol       Date:  2019-09-06

Review 6.  Islet cell transplant and the incorporation of Tregs.

Authors:  Adam Krzystyniak; Karolina Gołąb; Piotr Witkowski; Piotr Trzonkowski
Journal:  Curr Opin Organ Transplant       Date:  2014-12       Impact factor: 2.640

Review 7.  Cell-Based Therapies with T Regulatory Cells.

Authors:  Mateusz Gliwiński; Dorota Iwaszkiewicz-Grześ; Piotr Trzonkowski
Journal:  BioDrugs       Date:  2017-08       Impact factor: 5.807

8.  Engineering Cell Surfaces by Covalent Grafting of Synthetic Polymers to Metabolically-Labeled Glycans.

Authors:  Ruben M F Tomás; Benjamin Martyn; Trisha L Bailey; Matthew I Gibson
Journal:  ACS Macro Lett       Date:  2018-10-10       Impact factor: 6.903

9.  Engineering human stellate cells for beta cell replacement therapy promotes in vivo recruitment of regulatory T cells.

Authors:  D C Oran; T Lokumcu; Y Inceoglu; M B Akolpoglu; O Albayrak; T Bal; M Kurtoglu; M Erkan; F Can; T Bagci-Onder; S Kizilel
Journal:  Mater Today Bio       Date:  2019-05-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.